Glucans (e.g., Pullulan, Etc.) Patents (Class 536/123.12)
  • Patent number: 10792302
    Abstract: The present invention provides a prophylactic or therapeutic composition for a metabolic disorder, a composition for amplifying the amount of short-chain fatty acid in the intestine, or a composition for decreasing a ratio of bacteria belonging to the Firmicutes to bacteria belonging to the Bacteroidetes in the intestine, each containing an exopolysaccharide produced by Leuconostoc mesenteroides, and further, a food, a pharmaceutical product, a feed and the like containing the composition.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 6, 2020
    Assignee: Noster Inc.
    Inventors: Ikuo Kimura, Kenji Yamamoto, Keiko Hisa
  • Patent number: 10093952
    Abstract: The present invention provides a method for preparing yeast beta-D-glucan using a solubilization technology based on molecular assembly, comprising the following steps: (1) micro-fluidizing an enzymatic hydrolysate of yeast cell walls at 70 to 200 MPa, and then centrifuging to obtain a precipitate; (2) resuspending the precipitate obtained in step (1) with a ionic liquid, then dispersing to obtain a solution; wherein the ionic liquid is 1-ethyl-3-methylimidazolium acetate or 1-allyl-3-methylimidazolium chloride; (3) centrifuging the solution obtained in step (2), and then adding ethanol, centrifuging and collecting a precipitate; (4) resuspending the precipitate obtained in step (3) with water, then centrifuging and collecting a supernatant. Preferably, the method further comprises (5): spray drying the supernatant obtained in step (4) to obtain a yeast beta-D-glucan powder.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: October 9, 2018
    Assignee: Institute of Agro-Products Processing Science and Technology, CAAS
    Inventors: Qiang Wang, Hongzhi Liu, Li Liu, Aimin Shi, Hui Hu, Yanan Li, Weijing Lin, Yuquan Duan, Jie Gao, Xiaoyong Liu
  • Patent number: 10059778
    Abstract: The present invention is directed toward a process for making a poly alpha-1,3-glucan film. These films can be transparent or translucent and used in packaging applications.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: August 28, 2018
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Vindhya Mishra, T Joseph Dennes
  • Patent number: 9708417
    Abstract: Nanoparticles composed of water insoluble glucans and films composed of tile above nanoparticles, in addition, there is disclosed a process for producing nanoparticles composed of water insoluble glucans. Furthermore, surfactant stabilized nanoparticles composed of water insoluble glucans and films composed of the above nanoparticles. In addition, a process for producing surfactant stabilized nanoparticles composed of water insoluble glucans.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: July 18, 2017
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Ryan Cormier, Gregory L. Cote, Christopher D. Skory
  • Patent number: 9572363
    Abstract: The present invention includes a method for enhancing the taste of a food product, which includes the steps of culturing a submerged mycelial liquid tissue culture in a media, collecting the supernatant fluid of the submerged mycelial liquid tissue culture, and adding the collected supernatant fluid to a food product in an amount sufficient to enhance the food product's taste. In one embodiment, the mycelial liquid tissue culture comprises C. sinensis, and the culture step is carried out for between about one and sixty days. The food products include stevia plant parts, steviol glycoside, aspartame, acesulfame-K, sucralose, carbohydrates, monk fruit, cacao, cacao liquor, tea, ginseng, pea protein, sugar alcohol, coffee, cranberry, grapefruit, pomegranate, coconut, wine, beer, liquor and spirits. The present invention also includes products made by the disclosed methods.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: February 21, 2017
    Assignee: MYCOTECHNOLOGY, INC.
    Inventors: James Patrick Langan, Brooks John Kelly, Huntington Davis
  • Patent number: 9512239
    Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 6, 2016
    Assignee: TATE & LYLE INGREDIENTS FRANCE SAS
    Inventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
  • Patent number: 9345747
    Abstract: The present invention relates to a composition comprising at least one protein extract of hibiscus and/or at least one beta glucan or a salt thereof. Furthermore, the present invention relates to the use of said composition for the treatment of anal rhagades.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: May 24, 2016
    Assignee: THD
    Inventors: Filippo Bastia, Maurizio Saccomanno
  • Publication number: 20150111848
    Abstract: Method for preparing a branched glucan having a chain comprising a plurality of glucose units linked by alpha 1,4-glycoside bonds and a plurality of side-groups linked to said chain via another type of glycoside bonding, which side-groups comprise one or more glucose units, the method comprising contacting a glucose source with a polysaccharide—which polysaccharide is a glucan comprising a plurality of glucose units linked by alpha 1,4-glycoside bonds and is essentially linear or branched to a lesser extent than the branched glucan that is to be prepared—in the presence of an acid catalyst under polycondensation conditions, thereby forming the branched glucan.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 23, 2015
    Inventors: Maurice Karel Hubertina Essers, Johannes Wilhelmus Timmermans, Jerome Villarama Diaz, Ronald Tako Marinus van den Dool, Theodoor Maximiliaan Slaghek
  • Publication number: 20150099871
    Abstract: A method of extracting lentinan from lentinan containing mushrooms comprising the step of contacting the mushrooms with an ionic liquid so as to obtain a lentinan rich ionic liquid solution.
    Type: Application
    Filed: March 22, 2013
    Publication date: April 9, 2015
    Inventors: Martyn Earle, Manuela Gilea
  • Publication number: 20150045311
    Abstract: The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 12, 2015
    Inventor: Vincent D. Antle
  • Publication number: 20150038699
    Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a to pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Cargill, Incorporated
    Inventors: Jacques AndréChristian Mazoyer, Jean-Pierre Lhonneur
  • Publication number: 20150038697
    Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Cargill, Incorporated
    Inventors: Jacques André Christian MAZOYER, Jean-Pierre LHONNEUR
  • Publication number: 20150038696
    Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Cargill, Incorporated
    Inventors: Jacques André Christian MAZOYER, Jean-Pierre Lhonneur
  • Publication number: 20150038698
    Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Cargill, Incorporated
    Inventors: Jacques André Christian MAZOYER, Jean-Pierre LHONNEUR
  • Patent number: 8932616
    Abstract: Hydrophobic ?(1?4)glucopyranose polymers with enhanced degradation properties are described. Between the ?(1?4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: January 13, 2015
    Assignee: Surmodics, Inc.
    Inventor: Aleksey V. Kurdyumov
  • Publication number: 20150004140
    Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 1, 2015
    Inventors: Thierry NAEYE, Alexandra Eilnerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
  • Patent number: 8912168
    Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: December 16, 2014
    Inventor: Xin Ji
  • Patent number: 8912165
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: December 16, 2014
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Publication number: 20140364390
    Abstract: Described herein are compositions including xyloglucans as an active ingredient useful in the treatment of gastro-intestinal disorders or of disorders originating from the gastro-intestinal system and transferred to other systems, such as the genitourinary system. The compositions may have xyloglucans or an extract containing xyloglucans, and may further include other active ingredients.
    Type: Application
    Filed: November 27, 2013
    Publication date: December 11, 2014
    Applicant: Novintethical Pharma, Sagl
    Inventors: Marco Di Fulvio, Miguel Angel Alonso, Michele Giuseppe Di Schiena
  • Patent number: 8907080
    Abstract: Provided is a complex comprising a hydrophobic cluster compound and a ?-1,3-1,6-D-glucan having a degree of branching (a ratio of ?-1,6 linkages to ?-1,3 linkages) of 50 to 100%.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: December 9, 2014
    Assignees: Daiso Co., Ltd., Osaka City University, Osaka Prefecture University Public Corporation, Kyoto Prefectural Public University Corporation, National University Corporation Nara Institute of Science and Technology
    Inventors: Toshio Suzuki, Hideaki Ueda, Takeshi Nagasaki, Mitsunori Kirihata, Munenori Numata, Atsushi Ikeda
  • Patent number: 8901092
    Abstract: Embodiments of the invention include functionalized polysaccharides and compositions and structures including the same. In an embodiment, the invention includes an active agent delivery composition including a polysaccharide functionalized with a coupling group, wherein the polysaccharide lacks charged groups at a pH of between 6 and 8; and a complex comprising a nucleic acid and a transfection agent. In an embodiment, the invention includes an active agent delivery structure including a matrix comprising a polysaccharide covalently cross-linked through the residue of a coupling group on the polysaccharide, the polysaccharide lacking charged groups at a pH of between 6 and 8; and a nucleic acid delivery complex disposed within the active agent delivery structure. In an embodiment, the invention includes a material for medical applications including glycogen functionalized with coupling groups at a degree of substitution of between about 0.01 and 0.5. Other embodiments are also included herein.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: SurModics, Inc.
    Inventor: Joram Slager
  • Patent number: 8877737
    Abstract: The present invention provides an allergy inhibitor using the efficacy of amorphous paramylon which is a substance obtained by changing the crystalline structure of paramylon. The present invention relates to a substance for inhibiting allergic diseases. Amorphous paramylon of the present invention is an allergy inhibitor comprising amorphous paramylon which is obtained by amorphosizing crystalline paramylon derived from Euglena, and has a relative crystallinity of 20% or lower to the crystallinity of crystalline paramylon, determined by an X-ray diffractometry. This allergy inhibitor enables efficacious inhibition of allergic diseases such as atopic dermatitis, pollinosis, and the like.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: November 4, 2014
    Assignee: Euglena Co., Ltd.
    Inventor: Kengo Suzuki
  • Patent number: 8865888
    Abstract: A composite glucan is disclosed. The composite glucan of the present invention includes a mushroom glucan synthesized from a culture medium containing trehalose and mannose. The composite glucan of the present invention has great moisture retention and can be used in eye drops for alleviating xerophthalmia. A method for preparing a composite glucan is also disclosed.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: October 21, 2014
    Inventor: Shiu-Nan Chen
  • Patent number: 8865679
    Abstract: The present invention provides a means to broadly protect the military and the public from injury from biological warfare weapons, particularly infective agents such as anthrax. Beta (1,3)-glucans, particularly whole glucan particles, PGG-Glucan, and microparticulate glucan, provide general immune enhancement, thereby increasing the body's ability to defend against a wide variety of biological threats. Beta (1,3)-glucans have been shown to increase the resistance to infection by anthrax and other infectious organisms when administered before and after infection. The anti-infective mechanism of ?(1,3)-glucan appears to involve stimulation of the innate immune system through increased cytokine release and CR3 receptor activation. Beta (1,3)-glucan is pharmaceutically stable, relatively compact, and can also be used without significant side effects. Beta (1,3)-glucan can also enhance the effectiveness of other medical countermeasures such as antibiotics, vaccines, and immune antibodies.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: October 21, 2014
    Assignee: Biothera, Inc.
    Inventor: Gary R. Ostroff
  • Patent number: 8859759
    Abstract: Particulate ?-glucan is solubilized at elevated pressure and temperature to form particulate-soluble ?-glucan. The particulate-soluble ?-glucan is capable of being dried to a powder form and subsequently re-solubilized.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: October 14, 2014
    Assignee: Biothera, Inc.
    Inventor: Donald J. Cox
  • Patent number: 8846901
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 30, 2014
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: Gerold L. Mosher, James D. Pipkin, Douglas B. Hecker
  • Publication number: 20140274947
    Abstract: Methods and compositions relating to CDP-taxane conjugates are described herein.
    Type: Application
    Filed: September 19, 2013
    Publication date: September 18, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventors: Thomas C. Crawford, Oliver S. Fetzer, Lawrence Alan Reiter, Marc Wolfgang
  • Patent number: 8835403
    Abstract: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: September 16, 2014
    Inventors: Meiyu Geng, Huashi Guan, Xianliang Xin, Zhao Yang, Guangqiang Sun
  • Publication number: 20140256931
    Abstract: The present disclosure relates carbonaceous materials and to methods of using such carbonaceous materials for purifying oligomers produced from depolymerized biomass, such as lignocellulosic biomass.
    Type: Application
    Filed: October 18, 2012
    Publication date: September 11, 2014
    Applicants: BP CORPORATION NORTH AMERICA INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Po-Wen Chung, Alexandre Charmot, Alexander Katz, Amit A. Gokhal
  • Patent number: 8822432
    Abstract: A composition which can significantly accelerate equol production is provided. When formulated in a pharmaceutical preparation or a food or drink, this composition exerts effects of preventing a vascular disease by the cholesterol lowering function, preventing breast cancer or prostatic cancer, and preventing and/or treating osteoporosis. Also, when formulated in a feed or a pet food, the bone density is enhanced, so that it exerts effects to prevent weak legs of a pig, to strengthen egg shell of a laying hen, to prevent osteoporosis in a dog etc., and the like. It is a composition which comprises lactobionic acid, a salt of lactobionic acid or lactobionolactone as an active ingredient and a food or drink, a feed, a pet food or a pharmaceutical preparation, which contains the composition, and have effects to prevent and treat osteoporosis, an function to increase bone density, an effect to prevent breast cancer or prostatic cancer, and a cholesterol lowering function.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: September 2, 2014
    Assignee: Unitika Ltd.
    Inventors: Kenichi Oe, Takashi Kimura
  • Patent number: 8821934
    Abstract: The object of the present invention is to overcome conventional demerits of pullulan powders prepared by conventional techniques, i.e., they could not be homogeneously mixed with non-reducing saccharides composed of glucose units when mixed together, and the resulting mixtures do not easily dissolve in water; and to provide a pullulan-containing powder with an improved rate of water dissolution, as well as to provide preparations and uses thereof. The present invention solves the above object by providing a pullulan-containing powder which uniformly comprises pullulan as a main ingredient and a non-reducing saccharide, and their process and uses; wherein the pullulan-containing powder is prepared by the steps of preparing a solution dissolving pullulan and a non-reducing saccharide homogeneously, pulverizing the solution, and collecting the resulting pullulan-containing powder.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: September 2, 2014
    Assignee: Hayashibara Co., Ltd.
    Inventors: Toshiyuki Sugimoto, Toshio Miyake
  • Patent number: 8816067
    Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: August 26, 2014
    Assignee: Tate & Lyle Ingredients France SAS
    Inventors: Thierry Naeye, Alexandra Einerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
  • Publication number: 20140220078
    Abstract: This application concerns a method for preparing glucan from Aspergillus niger, characterised in that it comprises (i) the at least partial deacetylation of the mycelium of A. niger; (ii) acid treatment of the (partially) deacetylated mycelium, preferably following purification and/or washing, to obtain insoluble glucan and soluble chitosane, which acid treatment comprises placing the deacetylated mycelium in contact with an acidic solution; (iii) the separation of the soluble chitosan on the one hand, and the insoluble glucan on the other; (iv) alkaline treatment of the glucan comprising placing the glucan in contact with an alkaline solution to cause the glucans to flocculate; and (v) drying the flocculated glucans to obtain glucan powder. This invention further concerns the glucans thus obtained, compositions comprising them, and their uses. The glucans of the invention may be used as immunostimulants.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 7, 2014
    Applicant: KITOZYME
    Inventors: Philippe Richard Vaesen, Olivier Yvette Marcel Baum
  • Publication number: 20140219917
    Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 7, 2014
    Applicants: Emory University, Georgia State Research Foundation, Georgia Tech Research Corporation
    Inventors: Niren MURTHY, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
  • Patent number: 8791252
    Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: July 29, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong V. Cheung
  • Patent number: 8785621
    Abstract: A malleable compound according to the invention for use as a disinfectant comprises water, 25 to 40% by weight of a solvent component comprising low-molecular, water-miscible alcohols, 1 to 10% by weight of an active bactericidal component, 3 to 6% by weight hydroxypropylated polygalactomannan with an etherification level of between 0.3 and 1.5 and 0.1 to 0.5% by weight boracic acid or an equivalent amount of boron ions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 22, 2014
    Assignee: Joker AG
    Inventors: Meinrad Flury, Rene H. Dietrich
  • Publication number: 20140105935
    Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.
    Type: Application
    Filed: June 1, 2012
    Publication date: April 17, 2014
    Inventors: Nandita Bose, Anissa S.H. Chan
  • Publication number: 20140030277
    Abstract: This invention is directed to ?-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The ?-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicants: Whitehead Institute, The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston University, Massachusetts Institute of Technology
    Inventors: Ifat Rubin-Bejerano, Gerald R. Fink, Claudia Abeijon, Daniel S. Kohane, Jason E. Fuller, Robert S. Langer
  • Publication number: 20140031542
    Abstract: A composite glucan is disclosed. The composite glucan of the present invention includes a mushroom glucan synthesized from a culture medium containing trehalose and mannose. The composite glucan of the present invention has great moisture retention and can be used in eye drops for alleviating xerophthalmia. A method for preparing a composite glucan is also disclosed.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 30, 2014
    Inventor: Shiu-Nan Chen
  • Publication number: 20140023713
    Abstract: The invention relates to novel clathrate complexes of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene, possibly in ?-crystalline form, The clathrate complex may be in crystalline form, possibly in the form of nano-particles. In the clathrate complex, cyclodextrin is selected from ?-, ?-, ?- or hydroxypropyl-?-cyclodextrin, primarily ?-cyclodextrin. The proposed clathrate complexes make it possible to increase the water-solubility of the active compound, to improve the bioavailability, to reduce the dosage of the drug and, consequently, to reduce the toxic effect of 9-phenyl-sym-octahydroselenoxanthene. The complexes exhibit cytoradioprotective activity. The invention also relates to a liquid-phase and solid-phase methods for producing clathrate complexes, as well as to pharmaceutical compositions and drugs thereof.
    Type: Application
    Filed: February 20, 2012
    Publication date: January 23, 2014
    Inventors: Anatoliy Fedorovich Tsyb, Anna Yakovlevna Goncharova, Rahimdzhan Roziev, Ilya Vorobyev, Vladimir Podgorodnichenko, Kenes Erimbetov
  • Patent number: 8633170
    Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: January 21, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong V. Cheung
  • Publication number: 20140017732
    Abstract: The present application describes a dilute two-loop method for treating biomass in the production of biofuels such as ethanol. The method involves washing the biomass to dissolve sugars that are associated with the biomass, and separating the washed biomass into a solids phase and a liquids phase. The solids phase is pretreated to render the biomass more susceptible to hydrolysis under conditions that do not produce substantial amounts of sugars. The pretreated biomass is separated into a second solids phase and second liquid phase, and the second solids phase is saccharified and fermented. The first and second liquid phases are recycled to dilute the biomass at various stages of the process.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 16, 2014
    Applicant: Edeniq, Inc.
    Inventor: Edeniq, Inc.
  • Publication number: 20130316892
    Abstract: Provided are polymer particles which can be used at a high flow rate when used as a filler for chromatography, that is, has excellent resistance flow rate appropriate for processing in large quantities, and also has a high binding capacity for target molecules such as proteins when an appropriate ligand is contained in the particles, and a method for producing the polymer particles; specifically, crosslinked polymer particles and a method for producing the crosslinked polymer particles, polysaccharide composite particles and a method for producing the polysaccharide composite particles, a filler for chromatography using the polymer particles, and an adsorbent for antibody purification. Disclosed are: A.
    Type: Application
    Filed: December 14, 2011
    Publication date: November 28, 2013
    Applicant: JSR Corporation
    Inventors: Satoshi Nakamura, Tetsuo Fukuta, Kazuhiro Ikkyu, Yu Otani, Hiroshi Kawai
  • Patent number: 8592574
    Abstract: The present invention relates to a beta-glucan-based scaffold for biological tissue engineering using radiation fusion technology, and to a production method therefor. According to the production method of the present invention for beta-glucan-based scaffold, radiation fusion tissue engineering, a beta-glucan-aqueous solution is cast and is then irradiated in a crosslinking reaction in such a way as to form a gel or solid scaffold, thereby facilitating cell attachment and making it easy to create a biomimetic environment coinductive to the growth and differentiation of stem cells. Consequently, the beta-glucan-based scaffold according to the present invention can be usefully employed as a filler for tissue regeneration, cell culturing and plastic surgery, as a filler for voids in biological tissue, as a scaffold for reconstructive and corrective plastic surgery, and for cell transplantation and drug delivery.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 26, 2013
    Assignee: Quegen Biotech Co., Ltd.
    Inventors: Sung Ki Song, Yong Man Jang, In Ho Jeon, Sang Jin Ko, Jeong Rhan Jeon, Gie Taek Chun, Youn Mook Lim, Hui Jeong Kwon
  • Publication number: 20130310553
    Abstract: The present invention relates to novel methods for precipitating beta-glucan (?-glucan) by using high-molecular polyethylene glycol (PEG) and re-dissolving the precipitated ?-glucan in a suitable medium. The novel method of the present invention may also include drying the precipitated ?-glucan and/or swelling the precipitated b-glucan in a suitable solution before re-dissolving the ?-glucan.
    Type: Application
    Filed: May 14, 2013
    Publication date: November 21, 2013
    Applicant: Wintershall Holding GmbH
    Inventors: Tobias Käppler, Thorsten Haas, Julia Kristiane Schmidt, Christian Fleck, Stephan Freyer, Robert Bayer
  • Publication number: 20130302405
    Abstract: An object of the present invention is to provide a glucosamine-containing glucan, a modified product and a conjugate thereof. The glucosamine-containing glucan of the present invention is a glucosamine-containing glucan wherein the glucan has a plurality of non-reducing ends and at least one glucosamine residue is bound via an ?-1,4-bond to each of two or more non-reducing ends of the branched ?-1,4-glucan, but no glucosamine residue is present at a position other than the non-reducing ends of the branched ?-1,4-glucan, wherein the degree of polymerization of the glucan is 15 or more and 4×105 or less. The glucosamine-containing glucan of the present invention can be provided by allowing an ?-glucan phosphorylase to act on an aqueous solution comprising a branched ?-1,4-glucan and glucosamine-1-phosphate.
    Type: Application
    Filed: November 7, 2011
    Publication date: November 14, 2013
    Applicant: EZAKI GLICO CO., LTD.
    Inventors: Takeshi Takaha, Akiko Kubo, Michiyo Yanase
  • Patent number: 8580951
    Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: November 12, 2013
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S. M. Lu, Steven W. Shuey
  • Patent number: 8580954
    Abstract: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: November 12, 2013
    Assignee: Hospira, Inc.
    Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein
  • Patent number: 8580950
    Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 12, 2013
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S. M. Lu, Steven W. Shuey
  • Publication number: 20130295163
    Abstract: An object of the present invention is to provide a glucan containing at least one residue selected from an N-acetylglucosamine residue and a galactose residue, and a modified product. The branched glucan of the present invention is a branched glucan wherein the branched glucan has a plurality of non-reducing ends and at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an ?-1,4-bond to each of two or more non-reducing ends of the branched ?-1,4-glucan, but neither an N-acetylglucosamine residue nor a galactose residue is present at the position other than the non-reducing ends of the branched ?-1,4-glucan.
    Type: Application
    Filed: November 7, 2011
    Publication date: November 7, 2013
    Applicant: EZAKI GLICO CO., LTD.
    Inventors: Takeshi Takaha, Michiyo Yanase, Akiko Kubo, Haruyo Sambe, Ryo Kakutani